CIS Bladder Cancer Treatment in Singapore

Receiving a diagnosis of carcinoma in situ (CIS) of the bladder can feel overwhelming. This high-grade, non-muscle invasive bladder cancer requires prompt treatment to prevent progression. In Singapore, patients have access to established treatment protocols and experienced urologists who specialise in managing this challenging condition. Understanding your treatment options can help you feel more confident about the journey ahead.

CIS bladder cancer treatment refers to the comprehensive management approach for carcinoma in situ – a flat, high-grade cancer that grows on the bladder’s inner lining (urothelium). Unlike other bladder tumours that form visible growths, CIS spreads along the bladder surface like a sheet, making it challenging to detect and treat completely.

The primary treatment involves intravesical therapy – medications delivered directly into the bladder through a catheter. Bacillus Calmette-Guérin (BCG) immunotherapy remains the gold standard, stimulating the body’s immune system to attack cancer cells. Treatment protocols typically include an initial induction course followed by maintenance therapy to reduce recurrence risk.

For CIS bladder cancer, treatment success depends on complete response to therapy and vigilant long-term surveillance. Consulting a bladder specialist in Singapore supports personalised treatment planning aimed at achieving full remission while preserving bladder function and preventing progression to muscle-invasive disease.

Ideal Candidates

• Patients with biopsy-confirmed CIS of the bladder
• Those with adequate bladder capacity and function
• Individuals able to tolerate catheterisation procedures
• Patients committed to long-term follow-up protocols
• Those with good overall health status for treatment
• Non-smokers or those willing to quit smoking
• Patients without active urinary tract infections

Contraindications

• Active tuberculosis or recent BCG vaccination
• Immunocompromised states (HIV, organ transplant recipients)
• Gross haematuria (visible blood in urine)
• Traumatic catheterisation or recent bladder surgery
• Pregnancy or breastfeeding
• Severe bladder inflammation or reduced capacity
• Allergy to treatment components

Your urologist will conduct a thorough evaluation including medical history, physical examination, and necessary tests to determine if you’re suitable for CIS bladder cancer treatment. Individual factors such as previous treatments, concurrent conditions, and overall health status influence treatment planning.

BCG Immunotherapy

BCG (Bacillus Calmette-Guérin) immunotherapy represents the most effective intravesical treatment for CIS bladder cancer. This live attenuated tuberculosis vaccine stimulates a local immune response within the bladder, activating immune cells to recognise and destroy cancer cells. The treatment involves weekly instillations during the induction phase, followed by maintenance protocols that may continue for up to three years.

Intravesical Chemotherapy

For patients unable to receive BCG or those with BCG-refractory disease, intravesical chemotherapy offers an alternative approach. Agents like mitomycin C, gemcitabine, or docetaxel are instilled directly into the bladder. These medications work by directly killing cancer cells and preventing their replication. Some protocols combine chemotherapy agents or use them with hyperthermia to enhance effectiveness.

Combination Approaches

Recent protocols explore combination strategies to improve treatment outcomes. This may include alternating BCG with chemotherapy, using interferon alongside BCG, or employing device-assisted therapies. Electromotive drug administration (EMDA) uses electrical current to enhance drug penetration into bladder tissue.

Technology & Equipment Used

Modern cystoscopy equipment allows precise visualisation during treatment and follow-up. Photodynamic diagnosis (PDD) using blue light cystoscopy helps detect CIS areas that might be missed with standard white light. Some centres utilise hyperthermia devices that heat chemotherapy solutions to improve drug efficacy.

Pre-Treatment Preparation

Before starting CIS bladder cancer treatment, patients undergo comprehensive evaluation including urine cytology, cystoscopy, and imaging studies. You’ll need to provide urine samples to rule out infection. Smoking cessation is strongly encouraged as it improves treatment outcomes.

On treatment day, avoid excessive fluid intake two hours before your appointment. Empty your bladder before arriving. Wear comfortable clothing that allows easy access for catheterisation. Arrange transportation as some patients experience mild discomfort after treatment.

During the Procedure

The treatment begins with gentle catheter insertion to drain the bladder completely. Your healthcare provider then instils the medication (BCG or chemotherapy) through the catheter, which is immediately removed. The entire instillation process typically takes 10-15 minutes.

You’ll be asked to retain the medication in your bladder for two hours, changing position every 15-30 minutes to ensure the solution contacts all bladder surfaces. During this time, avoid urinating unless absolutely necessary. Most patients tolerate the procedure well with minimal discomfort.

Immediate Post-Treatment

After the two-hour retention period, you’ll urinate to expel the medication. For BCG treatment, specific toilet precautions are necessary – sitting to urinate (including men), adding bleach to the toilet bowl, and flushing twice. These precautions continue for six hours post-treatment.

Increase fluid intake to flush the bladder and reduce irritation. Mild burning during urination and urinary frequency are common immediate effects. Before discharge, you’ll receive specific instructions about symptom management and when to seek medical attention.

First 24-48 Hours

Most patients experience increased urinary frequency and mild burning sensation during the first two days. Drink plenty of water – at least 8-10 glasses daily – to dilute urine and reduce irritation. Avoid caffeine, alcohol, and spicy foods that may worsen bladder symptoms.

Mild flu-like symptoms including low-grade fever, fatigue, and body aches may occur with BCG treatment. Paracetamol usually provides adequate relief. Rest as needed but light activities are generally fine. Contact your healthcare provider if you develop high fever, severe pain, or blood in urine.

First Week

Bladder symptoms typically improve within 3-5 days after each treatment. Continue increased fluid intake and dietary modifications. Sexual activity can usually resume after 48 hours, but use protection as small amounts of medication may be present in body fluids.

Return to work and normal activities as tolerated. Many patients schedule treatments for Fridays to allow weekend recovery. Keep your follow-up appointment to assess treatment tolerance and address concerns before the next instillation.

Long-term Recovery

Between treatment cycles, most patients return to normal bladder function. Maintain good hydration habits and avoid bladder irritants. Smoking cessation remains crucial for treatment success and reducing recurrence risk.

Long-term surveillance includes regular cystoscopy every 3-4 months initially, with intervals extending based on response. Urine cytology helps monitor for recurrence. Maintenance therapy schedules vary but typically involve treatments at 3, 6, 12, 18, 24, 30, and 36 months after induction.

Intravesical therapy for CIS bladder cancer offers significant advantages over more invasive alternatives. BCG immunotherapy achieves complete response rates of 70-80% in appropriately selected patients, substantially reducing the risk of progression to muscle-invasive disease. This bladder-preserving approach maintains quality of life by avoiding major surgery.

The treatment directly targets cancer cells while minimising systemic side effects. Unlike systemic chemotherapy, intravesical therapy concentrates medication where needed most. This localised approach means patients can continue working and maintaining normal activities between treatments.

Long-term outcomes show that successful CIS treatment significantly reduces the risk of disease progression. Many patients achieve durable remissions, with some remaining disease-free for years. Regular surveillance allows early detection of recurrence, enabling prompt intervention when needed.

Common Side Effects

Bladder irritation affects most patients to some degree, causing urinary frequency, urgency, and mild burning. These symptoms typically occur for 24-48 hours after each treatment and improve with increased fluid intake. Low-grade fever and flu-like symptoms occur in about 30% of BCG recipients.

Mild blood in urine (haematuria) may appear but usually resolves quickly. Fatigue during treatment courses is common but manageable with adequate rest. Some patients develop mild joint aches or skin rashes that respond to simple measures.

Rare Complications

Severe BCG-related complications occur in less than 5% of patients. These include high fever lasting over 48 hours, severe bladder inflammation (BCG cystitis), or systemic BCG infection requiring antituberculous therapy. Allergic reactions to intravesical chemotherapy agents are uncommon but possible.

Bladder contracture from chronic inflammation rarely develops with proper treatment technique. Very rarely, BCG can cause inflammation in other organs including lungs, liver, or joints. Your urologist monitors for these complications through regular assessments and blood tests.

Risk minimisation involves careful patient selection, proper instillation technique, and adherence to safety protocols. Experienced urologists recognise early warning signs and adjust treatment accordingly. Most complications resolve completely with appropriate management.

CIS bladder cancer treatment costs vary based on the chosen therapy, treatment duration, and surveillance requirements. Factors include the medication type (BCG versus chemotherapy agents), frequency of treatments, and whether maintenance therapy is needed. BCG therapy generally costs less than newer chemotherapy options.

The complete treatment package typically includes medication costs, procedure fees, nursing care, and facility charges. Regular surveillance with cystoscopy and cytology adds to long-term expenses. Some patients require additional treatments if initial therapy proves insufficient.

Quality care from an experienced urology doctor in Singapore helps optimise treatment outcomes, potentially reducing the need for more costly interventions later. Many clinics offer package rates for complete treatment courses. During consultation, your urologist will provide a detailed cost estimate based on your specific treatment plan.